Bravecto Chewable Tablets for Dogs Very Large Dog (40 - 56kg) 1400mg (pack of 2)

Target species Dogs. Indications for use For the treatment of tick and flea infestations in dogs. This veterinary medicinal product is a systemic insecticide and acaricide that provides: -immediate and persistent flea (Ctenocephalides felis) killing activity for 12 weeks, -immediate and persistent tick killing activity for 12 weeks for Ixodes ricinus, Dermacentor reticulatus and D. variabilis, -immediate and persistent tick killing activity for 8 weeks for Rhipicephalus sanguineus. Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance. The onset of effect is within 8 hours of attachment for fleas (C. felis) and 12 hours of attachment for ticks (I. ricinus). The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). For the treatment of demodicosis caused by Demodex canis. For the treatment of sarcoptic mange (Sarcoptes scabiei var. canis) infestation. Contraindications Do not use in cases of hypersensitivity to the active substance or to any of the excipients. Special warnings for each target species Parasites need to start feeding on the host to become exposed to fluralaner; therefore the risk of the transmission of parasite borne diseases cannot be excluded. Special precautions for use Special precautions for use in animals Use with caution in dogs with pre-existing epilepsy. In the absence of available data, the veterinary medicinal product should not be used on puppies less than 8 weeks old and /or dogs weighing less than 2 kg. The product should not be administered at intervals shorter than 8 weeks as the safety for shorter intervals has not been tested. Operator warnings Keep the product in the original packaging until use, in order to prevent children from getting direct access to the product. Hypersensitivity reactions in humans have been reported. Do not eat, drink or smoke while handling the product. Wash hands thoroughly with soap and water immediately after use of the product. Adverse reactions Mild and transient gastrointestinal effects such as diarrhoea, vomiting, inappetence, and drooling were commonly observed in clinical trials (1.6% of treated dogs). Lethargy, muscle tremor, ataxia and convulsions have been reported very rarely in spontaneous reports. Most reported adverse reactions were self-limiting and of short duration. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). Use during pregnancy, lactation or lay The safety of the veterinary medicinal product in breeding, pregnant and lactating dogs has been demonstrated. Can be used in breeding, pregnant and lactating dogs. Interaction with other medicinal products and other forms of interaction Fluralaner is highly bound to plasma proteins and might compete with other highly bound active substances such as non-steroidal anti-inflammatory drugs (NSAIDs) and the coumarin derivative warfarin. Incubation of fluralaner in the presence of carprofen or warfarin in dog plasma at maximum expected plasma concentrations did not reduce the protein binding of fluralaner, carprofen or warfarin. During clinical field testing, no interactions between Bravecto chewable tablets for dogs and routinely used veterinary medicinal products were observed.